However, with traditional approaches in radiation therapy, safely delivering high radiation doses to a single target region and keeping it there long enough to completely eliminate the tumor has been, in most cases, impossible.
We have built a radiotherapeutic platform with the potential to overcome these challenges by directing higher, more powerful radiation doses at the tumor – and only the tumor. By minimizing radiation exposure to healthy tissues while simultaneously maximizing efficacy, we hope to reduce the toxicity of radiation for patients, improving their quality of life and giving them more time to enjoy it.
To inject high doses of radiation into or adjacent to brain and central nervous system (CNS) cancers, which then accumulate in the tumor, break down slowly to sufficiently destroy tumor tissue, and stay localized, sparing healthy tissues until fully cleared.
To inject high doses of radiation into solid organ cancers such as liver cancers, blocking the tumor’s blood supply, maintaining a localized attack on the tumor and then rapidly clearing the body without damage to healthy tissue.
BMEDA-chelated Rhenium-186, encapsulated in a nanoliposome carrier.
BMEDA-chelated Rhenium-188, encapsulated in a nanoliposome carrier and loaded into an alginate microsphere.
For patients with GBM and PBC, the size of our nanoliposome paired with Convection Enhanced Delivery (CED) allows rhenium (186Re) obisbemeda to bypass the blood-brain barrier and enhance drug distribution to a target region. For patients with LM, we administer rhenium (186Re) obisbemeda intraventricularly through the Ommaya reservoir, directly in the CNS compartment where the tumor is located.
We plan to develop and offer trans-arterial radioembolization in a minimally invasive, 2-step procedure where the drug is infused through a microcatheter into the hepatic artery, inducing highly selective tumor necrosis.